-transparent.png){kind=logo}
VM-26 was administered to 13 patients with metastatic adenocarcinoma of the kidney. Twelve of the 13 patients were assessable. The remaining patient was nonevaluable due to early death as defined in the protocol. No responses were observed in any of the 12 patients. Nonhematological toxicity was mild except for one instance of life-threatening hypotension, occurring during the infusion of VM-26. Significant leukopenia (less than 3000/mm3) occurred in 29% of courses and significant thrombocytopenia (less than 100,000/mm3) occurred in 14% of courses. Further studies using VM-26 in renal cell carcinoma do not seem warranted.
Related Publications
E A Hire, and
M K Samson, and
R J Fraile, and
L H Baker
May 1988,
Nihon Gan Chiryo Gakkai shi,
E A Hire, and
M K Samson, and
R J Fraile, and
L H Baker
January 1979,
Cancer treatment reports,
E A Hire, and
M K Samson, and
R J Fraile, and
L H Baker
December 1986,
Biochimica et biophysica acta,
E A Hire, and
M K Samson, and
R J Fraile, and
L H Baker
March 1979,
Cancer treatment reports,
E A Hire, and
M K Samson, and
R J Fraile, and
L H Baker
February 1990,
Investigational new drugs,
E A Hire, and
M K Samson, and
R J Fraile, and
L H Baker
October 1977,
Cancer treatment reports,
E A Hire, and
M K Samson, and
R J Fraile, and
L H Baker
March 1998,
Cancer,
E A Hire, and
M K Samson, and
R J Fraile, and
L H Baker
September 1997,
Cancer,
E A Hire, and
M K Samson, and
R J Fraile, and
L H Baker
May 1989,
Cancer biochemistry biophysics,
E A Hire, and
M K Samson, and
R J Fraile, and
L H Baker
March 1989,
Obstetrics and gynecology,
